Loading clinical trials...
Loading clinical trials...
A Phase II/III Randomized, Double-Blind, Placebo-Controlled, Cognitive Endpoint, Multi-Center Study of Potential Disease Modifying Therapies in Individuals at Risk for and With Dominantly Inherited Alzheimer's Disease
Conditions
Interventions
Gantenerumab
Solanezumab
+2 more
Locations
25
United States
University of Alabama in Birmingham
Birmingham, Alabama, United States
University of California San Diego Medical Center
La Jolla, California, United States
Yale University School of Medicine
New Haven, Connecticut, United States
Emory University
Atlanta, Georgia, United States
Indiana University School of Medicine
Indianapolis, Indiana, United States
Washington University in St. Louis
St Louis, Missouri, United States
Start Date
December 1, 2012
Primary Completion Date
November 22, 2019
Completion Date
March 6, 2020
Last Updated
September 22, 2022
NCT07545473
NCT07531732
NCT07170150
NCT07290387
NCT06121544
NCT06635876
Lead Sponsor
Washington University School of Medicine
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions